Get startedLog in
    Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logo

    1541 — ImmuneOnco Biopharmaceuticals (Shanghai) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Immuneonco Biopharmaceuticals Shanghai Gets Approval By NMPA For Phase II Clinical Trial Of IMM0306

    Picture of ImmuneOnco Biopharmaceuticals (Shanghai) logoImmuneOnco Biopharmaceuticals (Shanghai)
    02/12/2024 01:19
    Dec 2 (Reuters) - ImmuneOnco Biopharmaceuticals Shanghai
Inc  1541.HK :
    * APPROVAL BY NMPA FOR PHASE II CLINICAL TRIAL OF IMM0306
FOR
TREATMENT OF LUPUS NEPHRITIS


Further company coverage:  1541.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)

    See all news